How nerve cells affect pancreatic cancer growth
Official title: Peripheral Nerve Regulation of Pancreas Cancer Progression
Funded at University of Pittsburgh at Pittsburgh · NIH-11127669 · Data updated 2026-11-12
This work looks at how sensory and sympathetic nerve cells change immune responses and help pancreatic cancer progress.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $622,548 |
| NIH project number | 5R01CA285585-02 |
| Project ID | NIH-11127669 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with pancreatic ductal adenocarcinoma or those at high risk for pancreatic cancer would be the most relevant candidates for related future trials or sample collection.
✕Less likely to help
Individuals without pancreatic disease or with non-ductal pancreatic tumors are unlikely to receive direct benefit from this specific line of work in the near term.
What this research studies
Researchers will use mouse models that develop pancreatic ductal adenocarcinoma and laboratory assays to observe how sensory and sympathetic nerves interact with immune cells in early tumors. They will examine proteins on nerve cells that resemble immune checkpoint molecules and test whether those nerve signals change immune activity around tumors. The team will also study how innervation of nearby lymph nodes changes and whether those nerve changes help tumors grow. Overall, the project combines imaging, molecular assays, and tissue analysis to identify nerve-related targets that could be relevant to patients.
Why it matters
Potential benefit: If successful, this work could point to new ways to slow pancreatic cancer by targeting nerve-related signals or using nerve-based biomarkers to guide treatment.
How similar studies have gone: Previous animal studies showed that removing or blocking sensory nerves can slow pancreatic cancer progression in mice, but translating this finding to human therapies and targeting neuronal checkpoint proteins remains novel.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Saloman, Jami Lynn — University of Pittsburgh at Pittsburgh
- Study coordinator: Saloman, Jami Lynn
Related research
Other NIH-funded projects on the same topics.
-
SPORE in Pancreas Cancer at MSK: advancing personalized therapy for pancreatic cancer
A large, multi-year program at Memorial Sloan Kettering aims to tailor pancreatic cancer treatment to each patient’s biology to improve survival and outcomes.
-
How nerves influence pancreatic cancer progression and immune response
This NIH grant tests whether nerves and nerve signals affect pancreatic cancer growth and the body’s immune response, with findings that could lead to new therapies for people with pancreatic cancer.
-
Overcoming barriers in pancreatic cancer therapy
A cancer research project that explores how pancreatic tumors resist treatment and how to improve therapies by studying tumor cells and their surrounding environment in animal models.
-
How low oxygen makes pancreatic cancer cells more aggressive
This project looks at whether low oxygen areas inside pancreatic tumors cause cancer cells to become more aggressive and resist chemotherapy, aiming to help people with pancreatic cancer.
-
How different dietary fats affect pancreatic cancer start and growth
This project looks at whether specific kinds of high-fat diets speed up or slow the start and growth of pancreatic cancer to help people at risk understand dietary effects.
-
Immune signals that make pancreatic cancer more stem‑like and aggressive
Looking at whether an immune signal called IL‑22, working through its receptor IL‑22RA1 and STAT3, makes pancreatic ductal adenocarcinoma cells more stem‑like and aggressive to guide future treatments for people with PDAC.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.